<DOC>
	<DOCNO>NCT02862938</DOCNO>
	<brief_summary>This randomize , sham control , mask clinical trial 60 study participant glaucoma . Participants qualify study eye randomize screening baseline evaluation receive NT-501 encapsulate cell therapy ( ECT ) implant sham surgery ( control arm ) , explant require . An examination safety occur one day one week follow implant periodically thereafter 24 month post-implant . Based primary analysis data 6 month , patient control arm may offer NT-501 ECT implant 12 month time point .</brief_summary>
	<brief_title>Study NT-501 Encapsulated Cell Therapy Glaucoma Neuroprotection Vision Restoration</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<criteria>Patients must meet follow criterion join study ( eligibility criterion must meet screen baseline visit unless otherwise note ) : 1 . Participant must medically able undergo testing require schedule event ( SOE ) . 2 . Participant 's clinical diagnosis must consistent glaucoma 1. characterize follow feature : ) Clinical evidence progressive retinal ganglion cell ( RGC ) dysfunction degeneration use visual field least one structural modality establish : i. Glaucomatous visual field abnormality . ii . Mean deviation ( MD ) 3 15 dB . iii . Minimum average retinal nerve fiber layer ( RNFL ) thickness 60 μm maximum average RNFL 90 μm . b ) Residual visual field preservation include bestcorrected visual acuity ( BCVA ) good 20/200 eye . c ) Two visual field test adequate quality maximum visual field index ( VFI ) variability ± 10 % . 3 . Participant 's glaucoma must clinically stable , intraocular pressure ( IOP ) &lt; 21 . 4 . If participant two eye meet study criterion , bad eye determine visual field index ( VFI ) deem includable . If eye qualify VFI , randomization procedure assign one eye study . 5 . Participant must understand sign inform consent . If participant 's vision impair point he/she read informed consent document , document read participant entirety . 6 . Females childbearing potential must agree use effective form birth control . 7 . Participant must determine presurgical anesthesia medical team fit ophthalmic surgery NT501 ECT implant insertion . 1 . Participant unable comply study procedure followup visit . 2 . Participant optic nerve retinal degenerative disease cause vision loss , irrespective whether currently treat untreated . 3 . Participant visual loss le 20/200 nonstudy eye . 4 . Participant likely offer glaucoma surgery within 6 month screen . 5 . Participant optic nerve atrophy beyond modest pallor . 6 . Participant cataractassociated vision loss le 20/40 . 7 . Participant history ocular herpes zoster . 8 . Participant requirement acyclovir and/or relate product study duration . To eligible study , participant must discontinue use product prior enrollment must continue product complete study . 9 . Participant evidence corneal opacification lack optical clarity . 10 . Participant uveitis ocular inflammatory disease . 11 . Participant receive systemic steroid immunosuppressive medication . 12 . Participant diabetic macular edema and/or diabetic retinopathy . 13 . Participant myopic degeneration . 14 . Participant currently participate within last 3 month participate clinical trial drug ocular systemic administration . 15 . Participant pregnant lactating . 16 . Participant chemotherapy . 17 . Participant history malignancy basal cell carcinoma , unless treat successfully 2 year prior inclusion trial . 18 . Participant , opinion investigator , physical mental condition would increase risk participation study may interfere study procedure , evaluation outcome assessment . 19 . Participant choroidal neovascularization secondary age relate macular degeneration type retinal degeneration may interfere study procedure , evaluation outcome assessment . 20 . Any intraocular surgery study eye within 12 week prior screen visit 21 . History use drug know retinal toxicity , retinotoxic dos . 22 . Participant history current nonarteritic anterior ischemic neuropathy ( NAION ) 23 . Patient history multiple sclerosis . 24 . Participant glaucoma consider open angle glaucoma , pseudoexfoliation glaucoma pigmentary glaucoma..</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>